{
      "Rank": 3,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "Yes"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell"
      ],
      "ArmGroupInterventionName": [
            "Biological: Adult Autologous Mesenchymal Bone Marrow Cell"
      ],
      "ArmGroupLabel": [
            "Autologous Mesenchymal Bone Marrow Cell"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "Female",
            "Male"
      ],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT02165904"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [
            "Spain"
      ],
      "BaselineDenomCountGroupId": [
            "BG000"
      ],
      "BaselineDenomCountValue": [
            "10"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient"
      ],
      "BaselineGroupId": [
            "BG000"
      ],
      "BaselineGroupTitle": [
            "Autologous Mesenchymal Bone Marrow Cell"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [
            "Standard Deviation"
      ],
      "BaselineMeasureParamType": [
            "Mean",
            "Count of Participants",
            "Number"
      ],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [
            "Age, Continuous",
            "Sex: Female, Male",
            "Region of Enrollment"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "years",
            "Participants",
            "participants"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG000",
            "BG000",
            "BG000"
      ],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [
            "9.30"
      ],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [
            "42.2",
            "8",
            "2",
            "10"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The study goes on 24 months, with recruiting, treatment and follow period for all patients. The first day for each patient will be the first cellular administration. 3 doses will be administrated every 3 months from first dose.\n\nWhen the clinical trial finishes, it will be done a completed check of all obtained parameters."
      ],
      "BriefTitle": [
            "Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "May 2016"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Spinal Cord Injury"
      ],
      "ConditionAncestorId": [
            "D000013118",
            "D000002493",
            "D000009422",
            "D000020196",
            "D000014947"
      ],
      "ConditionAncestorTerm": [
            "Spinal Cord Diseases",
            "Central Nervous System Diseases",
            "Nervous System Diseases",
            "Trauma, Nervous System",
            "Wounds and Injuries"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC10",
            "BC26",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Nervous System Diseases",
            "Wounds and Injuries",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Spinal Cord Injury"
      ],
      "ConditionBrowseLeafId": [
            "M15068",
            "M15067",
            "M4894",
            "M16837",
            "M21176"
      ],
      "ConditionBrowseLeafName": [
            "Spinal Cord Injuries",
            "Spinal Cord Diseases",
            "Central Nervous System Diseases",
            "Wounds and Injuries",
            "Trauma, Nervous System"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000013119"
      ],
      "ConditionMeshTerm": [
            "Spinal Cord Injuries"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "It is a clinical trial phase I, single center, non-randomized, uncontrolled, open prospective follow-up of a cohort of patients with chronic spinal cord injury (SCI) .10 patients will be included with this injury.\n\nPrimary objective: Analyze the possible clinical efficacy of administration of main adult mesenchymal autologous cells expanded \"in vitro\" in patients with incomplete and chronically established SCI.\n\nSecondary objectives: Confirm the safety of treatment, and study possible changes in the cerebrospinal fluid (CSF) levels (Brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), Nerve Growth Factor 3 and 4(NT3 and NT4) after subarachnoid administration of BMMC."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nIncomplete SCI\nNeurological deficit clinically stable at least 12 months prior to treatment, and with a minimum of one-year evolution after SCI.\nNeurophysiological confirmation of incomplete SCI.\nThe MRI study that morphologically evaluate the SCI.\nAge between 18 and 70 years\nThread Men and women will compromise to use anticonceptive issues from first cell\u00b4s extraction to 6 months after last cell\u00b4s administration.\nAbility to attend clinical follow-up and perform physical therapy through the treatment period.\nWritten and signed informed consent, according to the local regulation.\nHematologic and creatinin parameters, SGOT and SGPT, within the normal range, according to laboratory standards considering that small variations could be accepted based on clinical study team criteria.\n\nExclusion Criteria:\n\nA classification in ASIA and FRANKEL clinical scales to evaluate the SCI.\nNeurophysiological records that confirm the complete SCI.\nAge below 18 years or above 70.\nPregnancy or lactation.\nMalignancy disease diagnosed or treated within the last 5 years.\nPatients with systemic disease that represents and additional risk to treatment.\nPatients with uncertain commitment to follow the physical therapy and clinical visits as well as patient with a negative input in the previous phycological assessment.\nInability to assess the SCI features through MRI either noise due to spinal stabilization systems or any other cause.\nPatients currently under hematopoietic growth factors treatment or who required or maintained anticoagulation.\nNeurodegenerative disease additional.\nHistory of substance abuse, psychiatric disease or allergy to the protein products used in the process of cell expansion.\nPositive serology for HIV and syphilis.\nActive Hepatitis B or Hepatitis C.\nWith other reason that would consider the patient ineligible for cell therapy according to the investigators judgment."
      ],
      "EnrollmentCount": [
            "10"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [
            "0"
      ],
      "EventGroupDeathsNumAtRisk": [
            "10"
      ],
      "EventGroupDescription": [
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient"
      ],
      "EventGroupId": [
            "EG000"
      ],
      "EventGroupOtherNumAffected": [
            "9"
      ],
      "EventGroupOtherNumAtRisk": [
            "10"
      ],
      "EventGroupSeriousNumAffected": [
            "1"
      ],
      "EventGroupSeriousNumAtRisk": [
            "10"
      ],
      "EventGroupTitle": [
            "Autologous Mesenchymal Bone Marrow Cell"
      ],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [
            "5"
      ],
      "EventsTimeFrame": [
            "2 years"
      ],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG000",
            "FG000"
      ],
      "FlowAchievementNumSubjects": [
            "10",
            "10",
            "0"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient"
      ],
      "FlowGroupId": [
            "FG000"
      ],
      "FlowGroupTitle": [
            "Autologous Mesenchymal Bone Marrow Cell"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "Yes"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [
            "Anonymized individual data of participants will be shared with Authorities at the end of the Clinical development plan by the CTD (Common Technical Document). Results will be published in a scientific publication"
      ],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Autologous Mesenchymal Bone Marrow Cell"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Adult Autologous Mesenchymal Bone Marrow Cell"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Analyze clinical efficacy of subarachnoid administration of",
            "autologous BMSC expanded \"in vitro\""
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "July 19, 2019"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 14, 2019"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Puerta de Hierro University Hospital"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Majadahonda"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Spain"
      ],
      "LocationFacility": [
            "Hospital Puerta de Hierro"
      ],
      "LocationState": [
            "Madrid"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "28222"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in Patients Suffering Incomplete Spinal Cord Injury (SCI)"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Puerta de Hierro University Hospital"
      ],
      "OrgStudyId": [
            "CME-LEM2"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment",
            "Systematic Assessment"
      ],
      "OtherEventNotes": [
            "Hypertension",
            "Local pain",
            "Leg pain",
            "Urinary tract infection",
            "Headache",
            "Hyperthermia",
            "Wound",
            "Infected pressure ulcer",
            "Arthralgia",
            "Syncope",
            "Pain in coccyx",
            "Neck pain",
            "Back pain",
            "Nasopharingytis",
            "Bronchitis",
            "Urinary retention"
      ],
      "OtherEventOrganSystem": [
            "Vascular disorders",
            "General disorders",
            "Musculoskeletal and connective tissue disorders",
            "Infections and infestations",
            "Nervous system disorders",
            "General disorders",
            "Injury, poisoning and procedural complications",
            "Infections and infestations",
            "Musculoskeletal and connective tissue disorders",
            "Nervous system disorders",
            "Nervous system disorders",
            "Musculoskeletal and connective tissue disorders",
            "Musculoskeletal and connective tissue disorders",
            "Infections and infestations",
            "Infections and infestations",
            "Renal and urinary disorders"
      ],
      "OtherEventSourceVocabulary": [
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)",
            "MedDRA (18.1)"
      ],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000",
            "EG000"
      ],
      "OtherEventStatsNumAffected": [
            "1",
            "1",
            "1",
            "2",
            "3",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1"
      ],
      "OtherEventStatsNumAtRisk": [
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10"
      ],
      "OtherEventStatsNumEvents": [
            "1",
            "1",
            "1",
            "2",
            "4",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1",
            "1"
      ],
      "OtherEventTerm": [
            "Hypertension",
            "Local pain",
            "Leg pain",
            "Urinary tract infection",
            "Headache",
            "Hyperthermia",
            "Wound",
            "Infected pressure ulcer",
            "Arthralgia",
            "Syncope",
            "Pain in coccyx",
            "Neck pain",
            "Back pain",
            "Nasopharingytis",
            "Bronchitis",
            "Urinary retention"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "before surgery",
            "3 months",
            "6 months",
            "9 months",
            "12 months",
            "6 months",
            "12 months",
            "before surgery",
            "6 months",
            "12 months",
            "before surgery",
            "6 months",
            "12 months",
            "before surgery",
            "6 months",
            "12 months",
            "baseline",
            "12 months",
            "BDNF before administration",
            "BDNF in month 10 after administration"
      ],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000"
      ],
      "OutcomeDenomCountValue": [
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10",
            "10"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient",
            "Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells expanded in vitro. Administrated by subarachnoid injection by lumbar puncture of 30x10^6 cells, and repeated at months 4, 7 and 10, reaching a total administration of 120x10^6 cells for each patient"
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000"
      ],
      "OutcomeGroupTitle": [
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell",
            "Autologous Mesenchymal Bone Marrow Cell"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "Sensitivity improvement was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS). The sum of MS, LTS, and PPS configure total ASIA score. A minimum possible score is 0 points. A maximum possible score is 224 points for a patient with normal sensation. ASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery. Mean and standard deviation for the 10 patients were obtained at all the time points and statistically analyzed.",
            "- Changes in Functional Independence Measure scale (NIF scale), score at the beginning, through and the end of the treatment.\n\nRanges score: 18 to 126. Being 18 total patient dependency and 126 total patient independence.",
            "- Changes in Barthel score at the beginning, through and the end of the treatment.\n\nRanges score: 0 to 100. Being 0 total patient dependency and 100 total patient independence.",
            "-Changes in IANC-SCIFRS scale\n\nRanges score: 0 to 48. Being 0 severe degree of disability and 48 normal value.",
            "- Changes in PENN score at the beginning, through and the end of the treatment\n\nRanges score: 0 to 4. Being 0 absence of spasms and 4 frequency greater than 10 spasms per hour.",
            "- Changes in ASHWORTH score at the beginning, through and the end of the treatment\n\nRanges score: 0 to 4. Being 0 when there isn\u00b4t increase in muscle tone when stretching, and 4 when there is rigid affected follow-up in flexion or extension",
            "\u2022 Changes in EVA score at the beginning, through and the end of the treatment\n\nRanges score: 0 to 10. Being 0 absence of pain and 10 the worst pain.",
            "changes in Geffner score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)\n\nRanges score: 0 to 6. Being 0 absence of bladder control and 6 total control of bladder",
            "changes in NBD score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)\n\nRanges score: 0 to 47. 0-6 is very minor dysfunction. 7-9 is minor dysfunction. 10-13 is moderate dysfunction; and 14 or more is severe dysfunction.",
            "Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as the number of patients that improved along the study.",
            "Urodynamic studies in terms of detrusor pressure (decrease on detrusor pressure is considered a clinical improvement)",
            "Urodynamic studies in terms of Bladder compliance. Bladder compliance is the result of a mathematical calculation of volume responsible for 1 cm H2O pressure rise measured during a cystometric filling\n\n. It gives an indication on how the different mechanisms in the bladder wall react on stretching.\n\nIt is obvious that compliance figures can vary widely in groups which makes it difficult to define limits of normality.",
            "Urodynamic studies in terms of Maximum cystometric capacity",
            "Number of patients with changes in morphology of injury compared with basal images",
            "- The safety will be valued with number of adverse events related with administration of subarachnoid autologous Bone Marrow Expanded Mesenchymal Cells in Incomplete Spinal Cord Injury (SCI).",
            "Changes in expression of neurotrophins in CSF (CerebroSpinal Fluid) samples obtained previously to first administration of cell therapy, and previously to the last administration, at month 10, in order to study the variability in the expression of neurotrophins along time. The mean+SD (standard deviation) at each time point was obtained. The tested neurotrophins were: BDNF."
      ],
      "OutcomeMeasureDispersionType": [
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation",
            "Standard Deviation"
      ],
      "OutcomeMeasureParamType": [
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Mean",
            "Number",
            "Mean",
            "Mean",
            "Mean",
            "Number",
            "Number",
            "Mean"
      ],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "measure before treatment (baseline visit), 3, 6, 9 and 12 months after surgery",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "Changes in IANC-SCIFRS scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "Changes in Geffner scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "Efficacy-measure before treatment (baseline visit), 6, and 12 months after surgery",
            "Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up",
            "measure before treatment (baseline visit), 6 and 12 months after surgery",
            "Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up",
            "before (baseline visit) and at 12 months",
            "Up to 12 months",
            "Basal and 10 months after the administration"
      ],
      "OutcomeMeasureTitle": [
            "Efficacy-Sensivity Improvement Using the ASIA Score",
            "Efficacy- Changes in Functional Independence Measure Scale",
            "Efficacy-Change in Barthel Score",
            "Efficacy-IANC-SCIFRS Scale",
            "Efficacy-Changes in PENN Score.",
            "Changes in ASHWORTH Score",
            "Efficacy-Changes in EVA Score",
            "Efficacy- Changes in Geffner Score",
            "Efficacy- Changes in NBD Score",
            "Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)",
            "Efficacy-Urodynammic in Terms of Detrusor Pressure",
            "Efficacy-Urodynamic Studies Bladder Compliance",
            "Efficacy-Urodynamic Studies Maximum Cystometric Capacity",
            "Efficacy-modification of Magnetic Resonance Imaging (MRI)",
            "Number of Adverse Events .",
            "Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Primary",
            "Secondary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [
            "units on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "score on a scale",
            "number of patients improved in SSEPs",
            "cm/H2O",
            "mL/cm H2O",
            "mL",
            "number of patients",
            "Adverse events",
            "pg/ml"
      ],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000",
            "OG000"
      ],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [
            "60",
            "63.7",
            "57.5",
            "51.84",
            "49.35",
            "33.9",
            "33.9",
            "33.9",
            "33.42",
            "32.05",
            "36.07",
            "36.07",
            "36.07",
            "36.07",
            "35.59",
            "9.96",
            "8.89",
            "9.73",
            "9.01",
            "8.21",
            "1.14",
            "1.10",
            "0.88",
            "0.88",
            "0.88",
            "0.81",
            "0.81",
            "0.81",
            "0.81",
            "0.99",
            "3.13",
            "1.16",
            "0.97",
            "0.84",
            "0.84",
            "1.34",
            "1.26",
            "1.14",
            "1.10",
            "1.23",
            "6.64",
            "4.15",
            "4.35",
            "3.86",
            "3.88",
            "20.08",
            "20.8",
            "37.22",
            "3.24",
            "3.36",
            "6.41",
            "156.26",
            "110.93",
            "183.6",
            "4.58",
            "49.65"
      ],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [
            "188.2",
            "202.2",
            "218.4",
            "228.9",
            "235.5",
            "95.7",
            "95.7",
            "95.7",
            "96.10",
            "98.6",
            "58",
            "58",
            "58",
            "58",
            "65",
            "29.10",
            "31.5",
            "33.90",
            "35.9",
            "36.9",
            "1.20",
            "1.10",
            "0.90",
            "0.90",
            "0.90",
            "1.4",
            "1.4",
            "1.4",
            "1.4",
            "1.10",
            "1.70",
            "0.70",
            "0.60",
            "0.40",
            "0.40",
            "3.30",
            "3.60",
            "3.80",
            "3.90",
            "4.20",
            "10.60",
            "6.10",
            "5.70",
            "4.40",
            "4.20",
            "7",
            "8",
            "68.6",
            "53.8",
            "51.5",
            "3.88",
            "6.14",
            "8.28",
            "234.9",
            "292.4",
            "292.6",
            "0",
            "0",
            "20",
            "19.14",
            "33.82"
      ],
      "OverallOfficialAffiliation": [
            "Hospital Universitario Puerta de Hierro-Majadahonda"
      ],
      "OverallOfficialName": [
            "Jes\u00fas JV Vaquero Crespo, M.D."
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1"
      ],
      "PointOfContactEMail": [
            "jesus.vaquero@salud.madrid.org"
      ],
      "PointOfContactOrganization": [
            "Hospital Universitario Puerta de Hierro Majadahonda, Madrid"
      ],
      "PointOfContactPhone": [
            "91 191 7760"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Dr. Vaquero Crespo"
      ],
      "PrimaryCompletionDate": [
            "May 2016"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Sensitivity improvement was measured using the ASIA (American Spinal Injury Association) scale to measure the Surface sensitivity (LTS), pain sensitivity (PPS), and the degree of motor function in key muscles (MS). The sum of MS, LTS, and PPS configure total ASIA score. A minimum possible score is 0 points. A maximum possible score is 224 points for a patient with normal sensation. ASIA score was obtained before surgery, and 3, 6, 9 and 12 months after surgery. Mean and standard deviation for the 10 patients were obtained at all the time points and statistically analyzed.",
            "- Changes in Functional Independence Measure scale (NIF scale), score at the beginning, through and the end of the treatment.\n\nRanges score: 18 to 126. Being 18 total patient dependency and 126 total patient independence.",
            "- Changes in Barthel score at the beginning, through and the end of the treatment.\n\nRanges score: 0 to 100. Being 0 total patient dependency and 100 total patient independence.",
            "-Changes in IANC-SCIFRS scale\n\nRanges score: 0 to 48. Being 0 severe degree of disability and 48 normal value.",
            "- Changes in PENN score at the beginning, through and the end of the treatment\n\nRanges score: 0 to 4. Being 0 absence of spasms and 4 frequency greater than 10 spasms per hour.",
            "- Changes in ASHWORTH score at the beginning, through and the end of the treatment\n\nRanges score: 0 to 4. Being 0 when there isn\u00b4t increase in muscle tone when stretching, and 4 when there is rigid affected follow-up in flexion or extension",
            "\u2022 Changes in EVA score at the beginning, through and the end of the treatment\n\nRanges score: 0 to 10. Being 0 absence of pain and 10 the worst pain.",
            "changes in Geffner score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)\n\nRanges score: 0 to 6. Being 0 absence of bladder control and 6 total control of bladder",
            "changes in NBD score before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)\n\nRanges score: 0 to 47. 0-6 is very minor dysfunction. 7-9 is minor dysfunction. 10-13 is moderate dysfunction; and 14 or more is severe dysfunction.",
            "Changes in the neurophysiological parameters (SSEPs, somatosensory evoked potentials) measured as the number of patients that improved along the study.",
            "Urodynamic studies in terms of detrusor pressure (decrease on detrusor pressure is considered a clinical improvement)",
            "Urodynamic studies in terms of Bladder compliance. Bladder compliance is the result of a mathematical calculation of volume responsible for 1 cm H2O pressure rise measured during a cystometric filling\n\n. It gives an indication on how the different mechanisms in the bladder wall react on stretching.\n\nIt is obvious that compliance figures can vary widely in groups which makes it difficult to define limits of normality.",
            "Urodynamic studies in terms of Maximum cystometric capacity",
            "Number of patients with changes in morphology of injury compared with basal images"
      ],
      "PrimaryOutcomeMeasure": [
            "Efficacy-Sensivity Improvement Using the ASIA Score",
            "Efficacy- Changes in Functional Independence Measure Scale",
            "Efficacy-Change in Barthel Score",
            "Efficacy-IANC-SCIFRS Scale",
            "Efficacy-Changes in PENN Score.",
            "Changes in ASHWORTH Score",
            "Efficacy-Changes in EVA Score",
            "Efficacy- Changes in Geffner Score",
            "Efficacy- Changes in NBD Score",
            "Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)",
            "Efficacy-Urodynammic in Terms of Detrusor Pressure",
            "Efficacy-Urodynamic Studies Bladder Compliance",
            "Efficacy-Urodynamic Studies Maximum Cystometric Capacity",
            "Efficacy-modification of Magnetic Resonance Imaging (MRI)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "measure before treatment (baseline visit), 3, 6, 9 and 12 months after surgery",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "Changes in IANC-SCIFRS scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "Changes in Geffner scale before surgery (baseline visit) and 3, 6, 9, 12 months after surgery (follow-up period)",
            "measure before treatment (baseline visit), 3, 6,9 and 12 months after surgery",
            "Efficacy-measure before treatment (baseline visit), 6, and 12 months after surgery",
            "Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up",
            "measure before treatment (baseline visit), 6 and 12 months after surgery",
            "Urodynamic studies before surgery, and at 6 and 12 months after surgery (follow-up",
            "before (baseline visit) and at 12 months"
      ],
      "ReferenceCitation": [
            "Vaquero J, Zurita M. Functional recovery after severe CNS trauma: current perspectives for cell therapy with bone marrow stromal cells. Prog Neurobiol. 2011 Mar;93(3):341-9. doi: 10.1016/j.pneurobio.2010.12.002. Epub 2010 Dec 14. Review.",
            "Otero L, Zurita M, Bonilla C, Aguayo C, Vela A, Rico MA, Vaquero J. Late transplantation of allogeneic bone marrow stromal cells improves neurologic deficits subsequent to intracerebral hemorrhage. Cytotherapy. 2011 May;13(5):562-71. doi: 10.3109/14653249.2010.544720. Epub 2011 Jan 5."
      ],
      "ReferencePMID": [
            "21163325",
            "21208021"
      ],
      "ReferenceType": [
            "background",
            "background"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Puerta de Hierro University Hospital"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Jes\u00fas Vaquero Crespo, M.D."
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Principal Investigator"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [
            "July 19, 2019"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "September 3, 2018"
      ],
      "ResultsFirstSubmitQCDate": [
            "May 14, 2019"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "2011-005684-24"
      ],
      "SecondaryIdDomain": [
            "2011-005684-24"
      ],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "Registry Identifier"
      ],
      "SecondaryOutcomeDescription": [
            "- The safety will be valued with number of adverse events related with administration of subarachnoid autologous Bone Marrow Expanded Mesenchymal Cells in Incomplete Spinal Cord Injury (SCI).",
            "Changes in expression of neurotrophins in CSF (CerebroSpinal Fluid) samples obtained previously to first administration of cell therapy, and previously to the last administration, at month 10, in order to study the variability in the expression of neurotrophins along time. The mean+SD (standard deviation) at each time point was obtained. The tested neurotrophins were: BDNF."
      ],
      "SecondaryOutcomeMeasure": [
            "Number of Adverse Events .",
            "Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Up to 12 months",
            "Basal and 10 months after the administration"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [
            "Systematic Assessment"
      ],
      "SeriousEventNotes": [
            "Acute Bronchitis"
      ],
      "SeriousEventOrganSystem": [
            "Respiratory, thoracic and mediastinal disorders"
      ],
      "SeriousEventSourceVocabulary": [
            "MedDRA"
      ],
      "SeriousEventStatsGroupId": [
            "EG000"
      ],
      "SeriousEventStatsNumAffected": [
            "1"
      ],
      "SeriousEventStatsNumAtRisk": [
            "10"
      ],
      "SeriousEventStatsNumEvents": [
            "1"
      ],
      "SeriousEventTerm": [
            "Bronchitis"
      ],
      "StartDate": [
            "May 2014"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "May 2019"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 18, 2014"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "May 6, 2014"
      ],
      "StudyFirstSubmitQCDate": [
            "June 12, 2014"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}